Cytosorbents (NASDAQ:CTSO) Receives Buy Rating from D. Boral Capital

Cytosorbents (NASDAQ:CTSO)‘s stock had its “buy” rating restated by stock analysts at D. Boral Capital in a research report issued on Tuesday,Benzinga reports. They presently have a $10.00 price target on the medical research company’s stock.

Separately, StockNews.com started coverage on shares of Cytosorbents in a research report on Wednesday, March 26th. They issued a “hold” rating for the company. Two research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Cytosorbents presently has a consensus rating of “Moderate Buy” and a consensus price target of $4.67.

Cytosorbents Price Performance

CTSO stock opened at $1.00 on Tuesday. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. The stock has a market capitalization of $54.68 million, a P/E ratio of -2.78 and a beta of 0.78. Cytosorbents has a fifty-two week low of $0.70 and a fifty-two week high of $1.61. The business has a 50-day moving average of $1.07 and a 200-day moving average of $1.05.

Cytosorbents (NASDAQ:CTSO) last released its quarterly earnings results on Monday, March 31st. The medical research company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.04. Cytosorbents had a negative return on equity of 118.54% and a negative net margin of 49.47%. The firm had revenue of $9.20 million during the quarter, compared to the consensus estimate of $10.09 million. On average, sell-side analysts anticipate that Cytosorbents will post -0.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cytosorbents

Large investors have recently made changes to their positions in the stock. Geode Capital Management LLC increased its holdings in Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after buying an additional 32,415 shares during the last quarter. Skylands Capital LLC increased its stake in shares of Cytosorbents by 1.0% during the 4th quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock worth $2,531,000 after purchasing an additional 26,195 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of Cytosorbents during the 4th quarter worth about $99,000. Renaissance Technologies LLC lifted its stake in Cytosorbents by 10.6% in the 4th quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock valued at $80,000 after purchasing an additional 8,400 shares during the last quarter. Finally, Avenir Corp grew its holdings in Cytosorbents by 4.0% during the fourth quarter. Avenir Corp now owns 3,093,946 shares of the medical research company’s stock worth $2,815,000 after purchasing an additional 118,387 shares during the period. Institutional investors and hedge funds own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.